Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases
Copyright © 2018. Published by Elsevier Inc.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 194(2018) vom: 15. Sept., Seite 75-79 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2018
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Research Support, Non-U.S. Gov't Hydroxychloroquine Mast cell activation diseases Mast cell activation syndrome Mast cells Mastocytosis Inflammation Mediators 4QWG6N8QKH |
| Résumé: | Copyright © 2018. Published by Elsevier Inc. There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators |
|---|---|
| Description: | Date Completed 14.08.2019 Date Revised 14.08.2019 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2018.07.004 |